1. Home
  2. UHS vs BMRN Comparison

UHS vs BMRN Comparison

Compare UHS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Health Services Inc.

UHS

Universal Health Services Inc.

HOLD

Current Price

$184.43

Market Cap

11.4B

Sector

Health Care

ML Signal

HOLD

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

HOLD

Current Price

$54.29

Market Cap

10.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHS
BMRN
Founded
1978
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4B
10.0B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
UHS
BMRN
Price
$184.43
$54.29
Analyst Decision
Buy
Buy
Analyst Count
12
18
Target Price
$230.25
$88.22
AVG Volume (30 Days)
760.3K
1.8M
Earning Date
04-27-2026
04-30-2026
Dividend Yield
0.43%
N/A
EPS Growth
37.34
N/A
EPS
23.10
1.80
Revenue
$17,364,829,000.00
$1,313,646,000.00
Revenue This Year
$7.70
$14.30
Revenue Next Year
$4.96
$11.65
P/E Ratio
$8.02
$30.90
Revenue Growth
9.71
17.62
52 Week Low
$152.33
$50.76
52 Week High
$246.33
$71.28

Technical Indicators

Market Signals
Indicator
UHS
BMRN
Relative Strength Index (RSI) 32.06 35.41
Support Level $181.18 $54.35
Resistance Level $189.57 $56.21
Average True Range (ATR) 5.34 1.65
MACD 0.04 -0.38
Stochastic Oscillator 14.29 11.67

Price Performance

Historical Comparison
UHS
BMRN

About UHS Universal Health Services Inc.

Universal Health Services primarily offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the US, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Share on Social Networks: